KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Capital Expenditures (2016 - 2025)

NovoCure's Capital Expenditures history spans 12 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 45.25% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $26.6 million, down 37.82%, while the annual FY2025 figure was $26.6 million, 37.82% down from the prior year.
  • Capital Expenditures for Q4 2025 was $4.9 million at NovoCure, down from $5.7 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $14.3 million in Q4 2021 and bottomed at $2.6 million in Q2 2021.
  • The 5-year median for Capital Expenditures is $6.3 million (2022), against an average of $7.1 million.
  • The largest annual shift saw Capital Expenditures surged 147.86% in 2021 before it crashed 54.95% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $14.3 million in 2021, then plummeted by 54.95% to $6.4 million in 2022, then increased by 6.06% to $6.8 million in 2023, then skyrocketed by 31.1% to $8.9 million in 2024, then tumbled by 45.25% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Capital Expenditures are $4.9 million (Q4 2025), $5.7 million (Q3 2025), and $5.5 million (Q2 2025).